Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
By Rong Yang, Jun Xu, Ligeng Xu, Xiaoqi Sun, Qian Chen, Yuhuan Zhao, Rui Peng, Zhuang Liu. ACS Nano, 2018
614 citations recorded by the source corpus.
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles with cancer cell membranes modified by mannose. Poly(d,l-lactide- co-glycolide) nanoparticles are first loaded with toll-like receptor 7 agonist, imiquimod (R837). Those adjuvant nanoparticles (NP-R) are then coated with cancer cell membranes (NP-R@M), whose surface proteins could act as tumor-specific antigens. With further modification with mannose moiety (NP-R@M-M), the obtained nanovaccine shows enhanced uptake by antigen presenting cells such as dendritic cells, which would then be stimulated to the maturation status to trigger antitumor immune responses. With great efficacy to delay tumor development as a prevention vaccine, vaccination with such NP-R@M-M in combination with checkpoint-blockade therapy further demonstrates outstanding therapeutic efficacy to treat established tumors. Therefore, our work presents an innovative way to fabricate cancer nanovaccines, which in principle may be applied for a wide range of tumor types.
Subfields: Biomedical Engineering, Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/26c4de277f3ea33f2db2ee63f569a6ab9b906bdb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Molecular Biology
Citations in the corpus
- Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “adjuvants to enhance “APC antigen presentation” and promote DC maturation that leads to the stimulation of cytotoxic T- cells that have anti-tumor function [122, 123].”
- Platinum-based drugs for cancer therapy and anti-tumor strategies (2022, background): “Notably, peptide-based drug delivery systems can enhance drug targeting properties and significantly reduce side effects [60, 61] due to their bioactivity and low immune response of peptides specifically expressed on tumor cell membranes [62-65].”